Custom Method Development

Metabolon Target

Custom Method Development

R Absolute Quantitation

R Rigorous Quality Control

R End-to-end Service

Absolute Quantitation for Your Specific Research Objectives

Metabolomics is a powerful tool for understanding biological systems and advancing disease treatments. Targeted panels—which provide absolute quantification on a subset of metabolites of interest—can answer specific research questions, uncover actionable insights, and propel new therapeutic developments. Sometimes, a targeted metabolomics panel may not exactly fit your analyte requirements: you may wish to analyze a non-validated matrix with greater confidence or prefer a narrower metabolite focus than what the available panel provides.

Customers interested in a bespoke list of analytes or who are working with unique samples or low analyte concentration can benefit from Metabolon’s Custom Method Development services for absolute quantification, allowing you to get the specific information you need without compromise—all while preserving the same advantages offered by Metabolon’s Targeted Panels.

Benefits of Custom Method Development

Accurate and reproducible measurements of a number of analytes or even a single analyte can be difficult, particularly if those analytes are present in low concentrations in a sample. With Metabolon’s Custom Method Development, you can rely on our experience to develop a new and customized method to meet your needs. Custom Targeted Panels and Single Analyte Assays can be developed and validated in practically any matrix. With custom offerings, sample preparation methods can be altered and different mass spectrometers can be leveraged to increase sensitivity, maximizing the detection and sensitivity of your analytes even when working with limited sample volumes.

These customized offerings enable investigators to answer specific research questions, uncover actional insights, and propel new therapeutic development, including novel diagnostic tests, using limited sample volumes, volatile analytes, and matrices that aren’t validated on existing commercial panels. Many of our customers are investigators and clinicians that use Custom Targeted Panels or Single Analyte Assays to inform clinical trial decision-making. When it comes time, regulatory submissions are easy because Metabolon’s methods can be designed for GCP-compliance, validated to FDA and EMA standards, and processed according to GCP/GCLP standards.

Delivering Absolute Quantification for Research and Biomarker Analysis

Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.

Sample Matrix Validation Details

Our Quality—ISO 9001:2015-certified Laboratory

Mtabolon offers three levels of sample validation: Exploratory (research-oriented, limited validation), RUO (Research Use Only), and GCP/GCLP (Good Clinical Practice / Good Clinical Laboratory Practice).

All methods at Metabolon are validated to adhere to Metabolon’s ISO 9001:2015-certified quality system. Validation experiments are based on the FDA, EMA, and ICH M10 Bioanalytical Guidance documents. All data are peer-reviewed, and a summary report containing the results of the validation experiment is provided.

For GCP/GCLP validation, all experiments and acceptance criteria strictly adhere to the FDA, EMA, and ICH M10 Bioanalytical Guidances. All GCP/GCLP studies are peer-reviewed and audited by the Metabolon Quality Assurance Department. A validation report containing all of the elements listed in the M10 Bioanalytical Guidance is provided.

The table below outlines all evaluated analytical performance parameters for Exploratory, RUO, and GCP/GCLP standards.

ISO 9001

Swipe left/right to view the full table.

Method Development Offerings
Evaluated Parameters Exploratory RUO GCP/GCLP
Linearity, Accuracy, and Precision of Calibration Standards ✓ (1 run) ✓ (3 runs) ✓ (3 runs)
QC Precision Accuracy ✓ (one level, precision only) ✓ (3 levels) ✓ (3 levels)
Lower Limit of Quantitation ✓ (1 run) ✓ (3 runs) ✓ (3 runs)
Selectivity ✓ (1 run) ✓ (3 runs) ✓ (3 runs)
Carryover ✓ (1 run) ✓ (3 runs) ✓ (3 runs)
Dilution Accuracy
Extraction Recovery (also used to show accuracy)
Sample Stability Testing—Benchtop Stability
Sample Stability Testing—Freeze/Thaw Stability
Secondary Instrument
Parallelism
Matrix Effect Testing
Specificity
Sample Stability Testing—Long-Term Stability
Extract Stability Testing
Run Injection Stability Testing
Solution Stability Testing
QA Review

Let Us Do The Hard Work For You

We work closely with our customers to develop custom panels purpose-built for their specific research needs. All custom panel projects begin with a one-on-one consultation to learn about our customer’s research program and the knowledge gaps a Single Analyte Assay can fill. We then generate the custom assay and run the samples, delivering the same high-quality customer service and data analysis and interpretation that comes with any project performed with Metabolon.

Why Metabolon?

Achieving absolute quantification for a panel of analytes in a reproducible, cost-effective, and timely manner can be challenging to achieve alone. With our decades of experience, a library of over 5,400 known metabolites, and clinical know-how we’re fully equipped to help you develop an accurate customized panel of analytes or Single Analyte Assay to answer your research question. Only Metabolon can support an investigator through the scientific paradigm of target discovery, interrogating thousands of metabolites with our Global Discovery Panel, through to target validation, using our suite of customizable targeted methods to derive actionable biological insights—all at the cost-effective scale necessary to support our customers’ needs.

Big Insights with Metabolon

Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.

Contact Us

Talk with an expert

Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.